Free Trial
NASDAQ:MRKR

Marker Therapeutics Q1 2024 Earnings Report

Marker Therapeutics logo
$1.55 +0.34 (+28.12%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.52 -0.03 (-1.63%)
As of 05/30/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marker Therapeutics EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Marker Therapeutics Revenue Results

Actual Revenue
$1.24 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Marker Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Marker Therapeutics' Q1 2025 earnings is scheduled for Wednesday, August 13, 2025

Marker Therapeutics Earnings Headlines

While others chase AI stocks, smart traders do this
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

View Marker Therapeutics Profile

More Earnings Resources from MarketBeat